Skip to content

Efficacy and Safety of Sevofran in Patients Scheduled for Elective Surgery Under General Anesthesia

A Multi-center, Open-Label, Randomized, Active-controlled, Parallel, Phase 4 Clinical Trial to Assess the Efficacy and Safety of Sevofran in Patients Scheduled for Elective Surgery Under General Anesthesia

Status
Completed
Phases
Phase 4
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01096212
Enrollment
178
Registered
2010-03-31
Start date
2008-09-30
Completion date
2010-03-31
Last updated
2010-03-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

General Anesthesia, Generic Drugs, Sevoflurane

Keywords

Efficacy, Minimum alveolar concentration, Safety, Sevoflurane

Brief summary

Sevoflurane is currently being used in more than 100 countries worldwide with an estimated 100 million operations having been performed using sevoflurane as a general anesthetic. After the expiry of the patent on sevoflurane as a pharmaceutical drug, a generic product (Sevofran®; Hana pharmacy, Co. Ltd, Seoul, Korea) has been launched. The aims of this study were to investigate the efficacy (mean minimum alveolar concentration), recovery characteristics (time to recovery of consciousness (ROC) and recovery, and BIS values at ROC and orientation), and safety (incidence and severity of adverse events) of generic sevoflurane in patients undergoing elective surgery.

Detailed description

Patients were randomly allocated to experimental group (generic sevoflurane) and active comparator group (original sevoflurane). Once in the operating room, patients were monitored with electrocardiography, non invasive blood pressure, pulse oximetry (Datex-Ohmeda S/5, Planar Systems, Inc., Beaverton, OR, USA) and BIS (Aspect 2000, Aspect Medical Systems, Inc., Newton, MA, USA). Anesthesia was induced with fentanyl (2 μg/kg) and propofol (2mg/kg). When patients were unconscious, original or generic sevoflurane was administered. Tracheal intubation was facilitated by administering rocuronium 0.6 mg/kg. The lungs of the patients were then ventilated with oxygen in air (1:2), and the ventilation rate was adjusted to maintain the end-tidal carbon dioxide partial pressure between 35 and 45 mmHg. The concentrations of carbon dioxide, sevoflurane, and oxygen were measured continuously using an infrared anesthetic gas analyzer (Datex-Ohmeda S/5, Planar Systems, Inc., Beaverton, OR, USA), which was calibrated before anesthesia for each patient using a standard gas mixture. The inspired concentration of sevoflurane was adjusted to maintain BIS values \< 60 and stable haemodynamics (systolic arterial pressure (SAP) \> 80 mmHg and heart rate (HR) \> 45 beats/min). Also, it was titrated to prevent signs of inadequate anesthesia (sweating, facial flushing, movement and swallowing, HR \> 90 beats/min without evidence of hypovolemia, and a 15 mmHg increase in SAP, compared with baseline SAP). Fentanyl 1 μg/kg was given if needed to resolve of signs of inadequate anesthesia. Concentration of compound A, formaldehyde, and methadone were measured at preset interval: 30, 60, 90, 120, 150, 180 min after administration of sevoflurane. Blood and urine samples were taken at preset interval for analyzing concentration of inorganic fluoride: 1 hr after administration of sevoflurane and every 2 hr during maintenance of anesthesia.

Interventions

DRUGoriginal sevoflurane

Sevoflurane content: 99.9985%, compound A: 4.6 ppm, water content (sample was opened, sealed and stored for 2 weeks): 0.072% w/v

DRUGgeneric sevoflurane

Sevoflurane content: 99.99%, compound A: 3.8 ppm, water content (sample was opened, sealed and stored for 2 weeks) : 0.044% w/v

Sponsors

National Clinical Research Coordination Center, Seoul, Korea
CollaboratorOTHER_GOV
Asan Medical Center
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
19 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients scheduled for elective surgery under general anesthesia * American Society Anesthesiologists Physical Status (ASA PS) 1 or 2 * Aged 19 years or above

Exclusion criteria

* ASA PS 3 or above * aged under 19 years * Contraindications against the use of sevoflurane * Abnormal laboratory finding with clinical significance * Evidence of pregnancy * History of alcohol or drug abuse * Hemoglobin \< 11 mg/dl * Neurological or psychiatric disease * Unable or unwilling to give informed consent

Design outcomes

Primary

MeasureTime frameDescription
Comparison of mean minimum alveolar concentration between original and generic sevofluraneDuring mainenance of anesthesia under general anesthesiaMinimum alveolar concentration was determined by end-tidal sevoflurane concentrations. Mean MAC was calculated as following equation, Mean MAC = (MAC \* hour) / (maintenance time from administration of hypnotic agent (propofol) for acquring loss of consciousness to extubation)

Secondary

MeasureTime frameDescription
Comparison of secondary efficacy and safety endpoints between two inhalation agentsDuring maintenance of anesthesia under general anesthesiaSecondary efficacy and safety characteristics include following items. 1. Anesthesia exposure: MAC \* hour \[Time frame: maintenanane period of anesthesia\] 2. Bispectral index, BIS \[Time frame: time to recovery of consciousnessn, time to recovery of orientation\] 3. Adverse event \[Time frame: maintenanane period of anesthesia\] 4. Incidence and severity of postopertive nausea and vomiting \[Time frame: 24 hours postoperatively\] 5. Concentrations of compound A, formaldehyde, methanol \[Time frame: 30, 60, 90, 120, 150, 180 min after sevoflurane administration\]

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 18, 2026